Previous 10 | Next 10 |
home / stock / lly / lly articles
Eli Lilly And Co (NYSE: LLY) has reported Q3 sales of $9.49 billion, up 37% Y/Y, beating the consensus of $8.95 billion, driven by growth...
Eli Lilly And Co (NYSE: LLY) has reported Q3 sales of $9.49 billion, up 37% Y/Y, beating the consensus of $8.95 billion, driven by growth...
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick...
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain right...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
The FDA approved Eli Lilly And Co's (NYSE: LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active ulcerative colitis (U...
Novo Nordisk A/S (NYSE: NVO) investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply l...
Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have dominated headlines in 2023 with increased interest and the impact being discussed...
After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-decli...
News, Short Squeeze, Breakout and More Instantly...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...